Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 304 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HPV Infections Clear all

Conditions: Papilloma Viral Infection, Vaccine Hesitancy, Communication
Interventions: HPV Message 1, HPV Message 2, HPV Message 3, Control Message, Provider Strong-Recommendation Toolkit; Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 9,002 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Common Warts (Verruca Vulgaris)
Interventions: Candin, Intradermal Solution, Placebo; Drug
Lead sponsor: Nielsen BioSciences, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 18
States / cities: Birmingham, Alabama • Bryant, Arkansas • Fort Smith, Arkansas + 15 more

Conditions: Herpes Simplex Infections, Human Papillomavirus, Epstein-Barr Virus Infections, Varicella-zoster Virus Infection, Cytomegalovirus Infections
Interventions: Gene-Eden-VIR/Novirin; Dietary Supplement
Lead sponsor: The Center for the Biology of Chronic Disease; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Valley Cottage, New York

Conditions: Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6, Cervical Cancer
Interventions: THEO; Other
Lead sponsor: Regenstrief Institute, Inc.; Other
Eligibility: 11 Years to 17 Years
Enrollment: 1,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Indianapolis, Indiana

Conditions: Warts
Interventions: Human Papillomavirus 9-valent Vaccine, Recombinant, Normal Saline; Biological · Other
Lead sponsor: Western Institute for Veterans Research; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Aids-related Malignancies, Lymphoma, Precancerous Condition, Sarcoma
Interventions: polymerase chain reaction, cytology specimen collection procedure, histological technique, colposcopic biopsy; Genetic · Other · Procedure
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 10
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 5 more

Conditions: Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV)
Interventions: Perianal and Digital Anorectal Exam, Cervical Swabs, Anal Swabs, High Resolution Anoscopy (HRA); Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Human Papillomavirus Infection
Interventions: Counseling; Behavioral
Lead sponsor: Le Bonheur Children's Hospital; Other
Eligibility: 9 Years to 99 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Cervical Cancer, Papilloma Viral Infection
Interventions: Stage 1 SOC, Stage 1 HERS, Stage 2 HERS, Stage 2 HERS+HC, Stage 3 SOC, Stage 3 HERS, Stage 3 HERS+HC, Stage 4 HERS, Stage 4 HERS+HC; Behavioral
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 546 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: New Brunswick, New Jersey • Philadelphia, Pennsylvania

Conditions: HIV Infection, Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Interventions: Cytology Specimen Collection Procedure, High Resolution Anoscopy with Biopsy, Laboratory Biomarker Analysis, Medical Examination, Physical Examination, Questionnaire Administration; Other · Procedure
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Papillomavirus Infections
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 30 Years to 50 Years · Female only
Enrollment: 409 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Common Warts
Interventions: 10% EISO, Placebo, 20% EISO, 30% EISO; Drug
Lead sponsor: ViroXis Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 20
States / cities: Rogers, Arkansas • Fremont, California • Lomita, California + 17 more

Conditions: Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
Interventions: Transoral surgery, intensity-modulated radiation therapy, cisplatin, carboplatin; Procedure · Radiation · Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 519 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 58
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 44 more

Conditions: Oropharyngeal Squamous Cell Carcinoma (OPSCCA), HPV (Human Papillomavirus)-Associated
Interventions: 39.6 Gy radiation; Radiation
Lead sponsor: Paul W. Read, MD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Anal Cancer, HIV Infection, Human Papilloma Virus Infection
Interventions: comparison of screening methods, laboratory biomarker analysis, questionnaire administration, quality-of-life assessment; Procedure · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older · Female only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 6 more

Conditions: Verruca Vulgaris
Interventions: 2014-ALC-919-US, Vehicle-Control Topical Solution; Drug
Lead sponsor: Veloce BioPharma LLC; Industry
Eligibility: 8 Years to 90 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Fort Washington, Pennsylvania

Conditions: Sexually Transmitted Infections, HIV Infections
Interventions: Not listed
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection, HIV Infection, Anal Cancer, Anus Neoplasms
Interventions: ABI-1968; Drug
Lead sponsor: Antiva Biosciences; Industry
Eligibility: 27 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: San Francisco, California • Orlando, Florida • Chicago, Illinois + 2 more

Conditions: Squamous Lntraepithelial Lesions of Vulva, Neoplasms, Squamous Cell, Vulvar HSIL
Interventions: E7 T Cell Receptor (TCR); Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HPV Infection
Interventions: Gardasil 9 2 dose regimen, Gardasil 9 3 dose regimen, Gardasil 9 rescue dose; Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 352 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infection
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 24 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Aurora, Colorado • Baltimore, Maryland • Boston, Massachusetts + 2 more

Conditions: Leukopenia, Neutropenia, Infections, Warts, Myelokathexis
Interventions: Mozobil (TM); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere); Drug · Combination Product
Lead sponsor: Marengo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Sacramento, California • Celebration, Florida • Miami, Florida + 10 more

Conditions: Infections, Papillomavirus
Interventions: Gynaecological follow-up, Cervarix, Placebo control; Procedure · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 28 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 3
States / cities: Iowa City, Iowa • Wichita, Kansas • Wenatchee, Washington

Search by objective public record fields.

Communication Strategies to Increase HPV Vaccinations

Candin for the Treatment of Common Warts

A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin

Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials

New Strategies to Assess Anal Cancer Risk In Women

Video-Assisted Counseling for HPV Vaccination

Reducing Urban Cervical Cancer Disparities

Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men

Natural History of Human Papillomavirus (HPV) Infections in Mid-Adult Women (WHIM)

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts

Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

OPSCC N0 Nodal Control With Reduced IMRT

Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV

ALC-919 For The Treatment Of Common Warts

Sexually Transmitted Infections Among African American Women Who Have Sex With Women

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen

Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects